Novel Ansamycin Antibiotics to combat AntiMicrobial Resistance

随着COVID-19大流行造成的死亡人数超过100万，地球仪各地的医疗保健系统正在努力科普，另一个问题即将出现，即抗菌素耐药性（AMR）。COVID-19大流行增加了抗生素的使用，因为抗生素被用于患者预防继发性细菌感染。这场大流行凸显了世界对重大医疗中断的准备程度，以及投资药物以应对这些中断的必要性。AMR已经是一个全球性问题，美国疾病控制和预防中心估计，每年有280万美国人因耐药性细菌而严重感染，35，AMR是一个日益严重的问题，具有巨大的社会和经济后果。病原菌对抗生素的耐药性越来越强，有些菌株现在对所有临床使用的抗生素都有耐药性。与此同时，新抗生素的发现和使用率有所下降。不幸的是，大多数大型制药公司都削减了他们的抗菌和抗感染药物开发计划，转而支持利润更高、风险更低的项目。Demuris是一家中小型企业，通过筛选大量放线菌细菌，发现了一种新型安莎霉素抗生素。它对多重耐药革兰氏阴性菌具有良好的效力，这是对公众最大的威胁。该项目将使该化合物的生产规模能够评估任何人类毒性和对一组医院病原体的效力。

As the death toll from the COVID-19 pandemic passes 1 million and healthcare systems around the globe are struggling to cope there is another problem on the horizon, of Antimicrobial Resistance (AMR). The COVID-19 pandemic has increased the usage of antibiotics due to being administered to patients for the prevention of secondary bacterial infections. The pandemic has highlighted how unprepared the world is for significant healthcare disruption and the need for investment in medicines to combat these disruptions.AMR was already a global problem, each year the US Centers for Disease Control and Prevention estimates that 2.8 million Americans acquire serious infections caused by antibiotic-resistant bacteria, and 35,000 of them die as a result.AMR is a growing problem with vast societal and economic consequences. Pathogenic bacteria are becoming increasingly resistant to antibiotics and some strains are now resistant to all clinically used antibiotics. At the same time, the rate of discovery and deployment of new antibiotics has declined. Unfortunately, most major pharmaceutical companies have curtailed their antimicrobial and anti-infective discovery programs in favour of more profitable, lower-risk programs.Demuris is a SME that through screening a large collection of actinomycete bacteria has identified a novel ansamycin antibiotic. It has good potency towards multi-drug-resistant Gram-negative bacteria ,which are greatest threat to the public. This project will enable the production of the compound at a scale which will enable the evaluation of any human toxicity and the potency towards a panel of hospital pathogens.